Transdermal administration kit

A transdermal drug delivery and kit technology, applied in the field of transdermal drug delivery kits, can solve the problem of not being able to maintain basal insulin through transdermal drug delivery, and achieve the effect of maintaining the level, cheap price, and slowly increasing the concentration

Active Publication Date: 2011-05-04
SUZHOU NANOMED BIOMED CO LTD
View PDF2 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to overcome the shortcomings in the current prior art that the basal insulin level in human blood cannot be maintained through transdermal administration, and to provide a transdermal drug delivery kit, so that the transdermal delivery of biosynthesized recombinant human insulin can be realized. Drug administration instead of injection administration of long-acting insulin analogue preparations to achieve the effect of maintaining stable basal insulin levels in human blood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal administration kit
  • Transdermal administration kit
  • Transdermal administration kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] This example is used to illustrate the preparation method of the transdermal drug delivery patch of the transdermal drug delivery kit provided by the present invention.

[0042] Take 40mg of Carbomer 980 powder and add 100IU / ml of Novolin Insulin (Novo Nordisk's recombinant human insulin) 0.4ml (equivalent to 1.4 mg of recombinant human insulin, at this time the weight ratio of drug support body to recombinant human insulin is 28.5: 1), after mixing evenly, spread on an area of At the center of the non-woven fabric (substrate) of 1.6cm×2.6cm (length×width), a rectangular drug holder and recombinant human insulin coating of 1cm×2cm (length×width) is formed, with a thickness of about 2mm, and A pressure-sensitive adhesive about 3mm wide is pasted on the edge of the non-woven fabric. The transdermal drug delivery patch used in the transdermal drug delivery kit of the present invention is obtained.

Embodiment 2

[0044] This example is used to illustrate the preparation method of the transdermal drug delivery patch of the transdermal drug delivery kit provided by the present invention.

[0045]Take 50g of pre-polymerized polydimethylsiloxane (Dow Corning, silicone elastomer, batch number: 0005002533) and add 0.25g of crosslinking agent (Dow Corning, silicone elastomer curing agent, batch number: 0005002533), mix well and pour it on a glass plate , so that it spreads evenly, with a thickness of 3mm, and a release agent is pre-added on the glass plate (Dow Corning silicon-based release agent, so that the made silicone rubber patch can be easily removed from the glass plate without adhesion); then Put it in a 50°C oven for 2 hours and take it out, peel off the polymerized silicone rubber, and cut the obtained silicone rubber film into a cuboid with a size of 2.6cm×1.6cm×2mm (length×width×height) according to the needs of administration , on two opposite surfaces of the silicon rubber memb...

Embodiment 3

[0048] This embodiment is used to illustrate the usage method of the transdermal drug delivery kit provided by the present invention.

[0049] Adopt successfully induced diabetic rats as a model, remove the hair of its abdomen after ether anesthesia, and clean it with normal saline, adopt the microneedle array (eight-sided conical microneedle, microneedle) in the transdermal drug delivery kit of the present invention The height is 100 μm, the density is 484 needles / square centimeter, the diameter of the needle tip is 1 μm, the width of the needle bottom is 100 μm, and the area is 1cm 2 , Suzhou Nasheng Microelectronics Co., Ltd.) and the microneedle propeller with a frequency of 6000-20000 times / min of longitudinal vibration act on the depilated part of the rat for 10 seconds, and then act on the adjacent part of the first acting position for another 10 seconds , the total area of ​​microneedle action is 1×2cm 2 . The transdermal patch is prepared according to the method of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
depthaaaaaaaaaa
heightaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention provides a transdermal administration kit, wherein the transdermal administration kit comprises a microneedle array and a transdermal administration patch; the penetration depth of the microneedle array into the skin is about 20 to 150 um; the transdermal administration patch comprises a medicament holder and insulin as active medicament components; the medicament holder is made from inert substances capable of adsorbing and holding the adsorbed liquid. The transdermal administration kit provided by the invention enables the blood sugar value of a rat suffering from diabetes mellitus to be kept constant during a period of from 2 to 24 hours after the rat is administered the formulation. So the transdermal administration kit provided by the invention can replace the hypodermic injection of protamine zinc insulin and other similar ways to maintain the stabilization of the basic insulin level in the human body blood.

Description

technical field [0001] The invention relates to a transdermal drug delivery kit. Background technique [0002] Insulin is a protein drug containing 51 amino acid residues. Normal human blood needs to maintain a certain concentration of insulin, that is, the basal insulin level. However, due to the loss of islet function in type I diabetics, in order to maintain a normal basal insulin level, long-term injections of medium and long-acting insulin and its analogue injections are required. Currently, medium and long-acting injections such as Danish Novo Nordisk’s N and Eli Lilly's N will have a peak effect after injection, which is likely to cause hypoglycemia in patients. Sanofi Aventis, France Although subcutaneous injection can achieve sustained 24-hour release without peak phenomenon, it is expensive. In addition, long-term and multiple injections not only bring pain and inconvenience to patients, but also tend to cause side effects such as inflammation and muscle atro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61M37/00A61D7/00A61K38/28
Inventor 高云华覃光炯徐百
Owner SUZHOU NANOMED BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap